An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs SC 004 (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AbbVie
- 22 Jun 2018 Planned number of patients changed from 108 to 174.
- 18 Jul 2017 Planned number of patients changed from 134 to 108.
- 18 Jul 2017 Planned End Date changed from 17 May 2021 to 15 Jun 2021.